Efficacy of Chlorella Vulgaris in Elderly Depressed Patients

Efficacy of short term consumption of Chlorella Vulgaris as an additive on severity of depression, anxiety and stress in elderly patients compared to control group

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161010030255N5

Enrollment

Registered

2022-06-18

Start date

2022-06-22

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depression. Major depressive disorder, recurrent, unspecified

Interventions

Intervention 1: Intervention group: Elderly patients aged 60 to 80 years old diagnosed with depression will be treated with 300 - 1200 milligrams of chlorella vulgaris for 12 weeks with their standard

Eligibility

Sex/Gender

All

Age

60 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients within the age range of 60-80 years Reading and writing ability Iranian nationality and ability to speak Persian Living with at least one family member Written consent from patient or family member Diagnosis of major depression based on DSM-V criteria certified by the research director (psychiatrist) that the patient has not been treated for depression at least in the past 4 weeks

Exclusion criteria

Exclusion criteria: Any serious cognitive disorder Developing any unpredictable and undesired physical or mental problem during treatment Consuming Warfarin and chemotherapeutic agents such as; Azathioprine, Basiliximab, Cyclosporine, Daclizumab, Muromonab- CD3, Mycophenolate, Tacrolimus History of drug and alcohol abuse Uncontrolled diabetes or thyroid problem

Design outcomes

Primary

Measure	Time frame
Severity of depression based on Geriatric Depression Scale (GDS). Timepoint: Baseline data, after 6 and 12 weeks. Method of measurement: Persian version of Geriatric Depression Scale (GDS).;Severity of depression based on Depression, Anxiety, Stress Scales (DASS). Timepoint: Baseline data, after 6 and 12 weeks. Method of measurement: Persian version of Depression, Anxiety, Stress Scales (DASS).;Severity of anxiety based on Depression, Anxiety, Stress Scales (DASS). Timepoint: Baseline data, after 6 and 12 weeks. Method of measurement: Persian version of Depression, Anxiety, Stress Scales (DASS).;Severity of stress based on Depression, Anxiety, Stress Scales (DASS). Timepoint: Baseline data, after 6 and 12 weeks. Method of measurement: Persian version of Depression, Anxiety, Stress Scales (DASS).	—

Measure

Time frame

Severity of depression based on Geriatric Depression Scale (GDS). Timepoint: Baseline data, after 6 and 12 weeks. Method of measurement: Persian version of Geriatric Depression Scale (GDS).;Severity of depression based on Depression, Anxiety, Stress Scales (DASS). Timepoint: Baseline data, after 6 and 12 weeks. Method of measurement: Persian version of Depression, Anxiety, Stress Scales (DASS).;Severity of anxiety based on Depression, Anxiety, Stress Scales (DASS). Timepoint: Baseline data, after 6 and 12 weeks. Method of measurement: Persian version of Depression, Anxiety, Stress Scales (DASS).;Severity of stress based on Depression, Anxiety, Stress Scales (DASS). Timepoint: Baseline data, after 6 and 12 weeks. Method of measurement: Persian version of Depression, Anxiety, Stress Scales (DASS).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Victoria Omranifard

Esfahan University of Medical Sciences

v_omranifard@med.mui.ac.ir+98 31 3668 8789

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026